Regarding TTV, one study showed persistent seroresponse in patients treated with TNFi; a second study showed no difference between MTX and RTX in response to T-cell dependant protein Ag TTV. Two studies reported no significant difference in efficiency or tolerance in patients accidentally revaccinated against yellow fever under TNFi. Conclusions: These observations highly suggest that an effective vaccination for patients treated with MTX, RTX, and ABA should necessitate a therapeutic window or a scheduled treatment spacing, in order to offer the best protection against Influenza and Pneumococcal infection. This might not be necessary in patients under TNFi or TCZ; nevertheless, further studies are necessary to optimize the vaccination modalities.
Conclusions:
This was the first study using the TFEQ in patients with RA. In our study, we found that disease features of RA may had no effect on eating behaviors. At 12 months (v12) the joint assessment (DAS28), echocardiogram, PTF and HRCT were again evaluated. HRCT's were assessed by the same radiologist with expertise in chest radiology. Outcomes: At v12:(1)improvement (ie improvement in FVC≥10% or DLCO≥15% and no radiological progression),(2)non-progression (stabilization or improvement in FVC≤10% or DLCO<15% and no radiological progression),(3)progression (worsening of FVC>10% or DLCO>15% and radiological progression), or (4) death due to ILD. Variables: Description of ILD type (Nonspecific interstitial pneumonia/Usual interstitial pneumonia) and lung function by PTF, HRCT.Presence of PTH by echocardiogram and dyspnoea.Collection of adverse events. Statistical analysis: Descriptive analysis and Wilcoxon or T test between the v0 and v12. One factor ANOVA between sDMARD,bDMARD and combination therapy groups.
Results:
The main characteristics at V0 of the patients (n=22) are shown in the table. Seven patients (31.8%) received a sDMARDs with a bDMARDs; 12 patients (54.5%) in monotherapy with sDMARD, with MTX being the most frequent (34.7%); 3 (13.6%) in monotherapy with bDMARDs (Table 1) There were no significant differences in PTF, HRCT or DAS28 at v12 between sDMARD, bDMARD and combination therapy groups. Four patients (18.2%) had adverse effects: 2 respiratory infections, 1 oral herpes simplex and 1 tooth infection.
Conclusions:
Most patients with RA and ILD who are receiving treatment with DMARD (82%)remained stable or improved after at least 1 year of both synthetic and biological DMARD treatment. However, a significant percentage of patients had an adverse outcome. More prospective studies with a greater number of patients are necessary to identify the influence of DMARDs in this evolution. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5824
